Pharming Group (NASDAQ:PHAR) Shares Gap Up – What’s Next?

Pharming Group (NASDAQ:PHAR)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $9.09, but opened at $9.50. Pharming Group shares last traded at $9.64, with a volume of 3,700 shares changing hands.

Analyst Upgrades and Downgrades

PHAR has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Tuesday, December 17th. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Oppenheimer cut their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th.

Pharming Group Trading Down 2.9 %

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $611.96 million, a P/E ratio of -34.70 and a beta of -0.08. The stock has a 50 day simple moving average of $8.99 and a 200-day simple moving average of $8.43.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.